文献速递病毒性肝炎

乙型肝炎核心抗体水平与慢性乙型肝炎患者肝脏炎症及聚乙二醇干扰素治疗应答相关

Levels of Antibodies to Hepatitis B Core Antigen Are Associated With Liver Inflammation and Response to Peginterferon in Patients With Chronic Hepatitis B.
PubMed 文献 · J Infect Dis · 2022-01-01

研究评估390例慢性乙型肝炎患者聚乙二醇干扰素(PEG-IFN)治疗前抗-HBc水平与血清标志物、肝组织学及治疗应答的关系。结果显示抗-HBc与炎症活动度相关,较高抗-HBc与HBeAg清除、持续应答、HBsAg下降及清除相关。作者认为抗-HBc可用于筛选最可能对免疫调节治疗应答的患者。

要点

  • 在未治疗的HBeAg阳性患者中,抗-HBc与HBV DNA、HBcrAg、HBsAg及HBV RNA相关,与ALT无关。
  • 较高抗-HBc与更严重的组织学炎症活动度相关(P < .001),不受HBeAg状态影响。
  • de novo PEG-IFN治疗后,较高抗-HBc与HBeAg清除、持续应答、HBsAg下降及清除相关(P < .050)。

核心结论

  • 血清抗-HBc水平与组织学炎症活动度相关,较高抗-HBc水平与有利的治疗结局相关。
  • 作者认为抗-HBc可用于筛选最可能对免疫调节治疗应答的患者。

研究设计与样本

  • 评估慢性乙型肝炎患者PEG-IFN治疗前抗-HBc水平,分为de novo PEG-IFN组(n = 299,其中195例HBeAg阳性)和PEG-IFN联合核苷(酸)类似物组(n = 91,均为HBeAg阳性)。
  • 共研究390例患者,探索抗-HBc与血清标志物、肝组织学表现及治疗应答之间的关联。

主要发现

  • HBV基因型A、B、C、D分别占24%、9%、16%、49%,72%患者为白人。
  • 在未治疗的HBeAg阳性患者中,抗-HBc与HBV DNA、HBcrAg、HBsAg及HBV RNA相关,与ALT无关。
  • 较高抗-HBc与更严重的组织学炎症活动度相关(P < .001),不受HBeAg状态影响。
  • de novo PEG-IFN治疗后,较高抗-HBc与HBeAg清除、持续应答、HBsAg下降及HBsAg清除相关(P < .050)。
  • 在PEG-IFN联合治疗组中,较高抗-HBc与HBeAg清除相关(P = .01)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Emerging evidence suggests a pivotal role for B-cell responses in the natural history of chronic hepatitis B. Serum levels of antibodies to hepatitis B core antigen (anti-HBc) vary across infection stages, but their role in predicting response to antiviral therapy is uncertain. METHODS: Anti-HBc levels were assessed before peginterferon (PEG-IFN) therapy in patients with chronic hepatitis B who either started de novo PEG-IFN (n = 299; 195 hepatitis B e antigen [HBeAg] positive) or started PEG-IFN as add-on to an existing nucleo(s)tide analogue backbone (n = 91; all HBeAg-positive). Associations were explored between anti-HBc and (1) serum biomarkers, (2) liver histological findings, and (3) treatment response. RESULTS: We studied 390 patients. The hepatitis B virus (HBV) genotype were A, B, C, and D in 24%, 9%, 16%, and 49%, respectively; 72% of patients were Caucasian. Among currently untreated HBeAg-positive patients, anti-HBc was correlated with HBV DNA, hepatitis B core-related antigen (HBcrAg), hepatitis B surface antigen (HBsAg), and HBV RNA, but not with alanine aminotransferase (ALT). Higher anti-HBc was associated with more severe histological inflammatory activity (P < .001), irrespective of HBeAg status. After de novo PEG-IFN, higher anti-HBc levels were associated with HBeAg loss, sustained response, HBsAg decline, and HBsAg clearance (P < .050). Among patients treated with add-on PEG-IFN, higher anti-HBc was associated with HBeAg loss (P = .01). CONCLUSIONS: Serum anti-HBc levels correlate with histological inflammatory activity. Higher anti-HBc levels were associated with favorable treatment outcomes. These findings suggest that anti-HBc could be used to select patients most likely to respond to immunomodulatory therapy. CLINICAL TRIALS REGISTRATION: NCT00114361, NCT00146705, NCT00877760, and NCT01532843.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Brakenhoff SM, de Knegt RJ, Oliveira J, et al. Levels of Antibodies to Hepatitis B Core Antigen Are Associated With Liver Inflammation and Response to Peginterferon in Patients With Chronic Hepatitis B. J Infect Dis. 2022. PMID: 35599306. doi:10.1093/infdis/jiac210

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。